• Jennifer Tousignant, chief legal officer at Viridian Therapeutics, sold 14,212 common shares at USD 24.5 on Aug. 19.
• Transaction included a 10,000-share option exercise at USD 14.41, followed by a sale of the same number of shares.
• She reported 0 common shares owned following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-359636), on August 20, 2026, and is solely responsible for the information contained therein.